|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Eisai Medical Research Inc. |
| Information provided by: | Eisai Medical Research Inc. |
| ClinicalTrials.gov Identifier: | NCT00069264 |
Purpose
To determine the maximum tolerated dose of E7389 in patients with advanced solid tumors that have progressed following standard therapy or for which no standard therapy exists.
| Condition | Intervention | Phase |
|
Advanced Solid Tumors |
Drug: E7389 |
Phase I |
| MedlinePlus related topics: | Cancer |
| Drug Information available for: | E7389 |
| Study Type: | Interventional |
| Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
| Official Title: | A Phase I Dose-Finding Study of E7389 (Halichondrin B Analog) in Patients With Advanced Solid Tumors |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Exclusion Criteria
Contacts and Locations| United States, New York | |||||
| Bronx, New York, United States, 10461 | |||||
| United States, Texas | |||||
| San Antonio, Texas, United States | |||||
| Eisai Medical Research Inc. |
| Study Director: | Dale Shuster, Ph.D. | Eisai Medical Research Inc. |
More Information
Related Info 
  |
| Study ID Numbers: | E7389-A001-101, E7389, BOLD |
| First Received: | September 19, 2003 |
| Last Updated: | January 29, 2008 |
| ClinicalTrials.gov Identifier: | NCT00069264 |
| Health Authority: | United States: Food and Drug Administration |
|
|